Poolbeg Pharma PLC Market Cap ($603.77K)
Market Cap & Net Worth: Poolbeg Pharma PLC (POLB)
Poolbeg Pharma PLC market cap. Poolbeg Pharma PLC (LSE:POLB) has a market capitalization of $603.77K (GBX4.96 Billion) as of November 1, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30979 globally and #894 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poolbeg Pharma PLC's stock price GBX6.50 by its total outstanding shares 763437106 (763.44 Million). Also see Poolbeg Pharma PLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Poolbeg Pharma PLC Market Cap History (2021–2026)
Poolbeg Pharma PLC market cap history from 2021 to 2026. Data shows change from $882.44K to $603.77K (-9.08% CAGR). Check POLB live share price for real-time trading data and today's change.
Index Memberships
Poolbeg Pharma PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$993.18 Million | 0.06% | #205 of 722 |
Weight: Poolbeg Pharma PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Poolbeg Pharma PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poolbeg Pharma PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Poolbeg Pharma PLC (POLB) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of POLB by Market Capitalization
Companies near Poolbeg Pharma PLC in the global market cap rankings as of November 1, 2026. Also see Poolbeg Pharma PLC total assets for a full breakdown of the balance sheet.
Key companies related to Poolbeg Pharma PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Poolbeg Pharma PLC (2021–2026)
Market capitalization of Poolbeg Pharma PLC from 2021 to today. Between 2021 and today, Poolbeg Pharma PLC's market cap moved from $882.44K to $ 603.77K, with a yearly change of -9.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX603.77K | +62.50% |
| 2025 | GBX371.55K | -43.66% |
| 2024 | GBX659.51K | -21.55% |
| 2023 | GBX840.64K | +49.59% |
| 2022 | GBX561.97K | -36.32% |
| 2021 | GBX882.44K | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Poolbeg Pharma PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $603.77K USD |
| MoneyControl | $603.77K USD |
| MarketWatch | $603.77K USD |
| marketcap.company | $603.77K USD |
| Reuters | $603.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more